Objective: BRCA carriers are recommended to undergo prophylactic risk-reducing salpingo-oophorectomy (RRSO). Possible adverse health impacts of RRSO, particularly when done before natural menopause, can reduce the long-term satisfaction with this risk-reducing strategy. The aim of this study was to prospectively evaluate the level of satisfaction of women undergoing RRSO, also in relation to some specific characteristics at RRSO.
Methods: A prospective cohort study was performed in the Modena Family Cancer Clinic of the University Hospital of Modena (Italy). All BRCA1/2 confirmed mutation carriers who decided to undergo RRSO were recruited between 2016 and 2019.
Results: Fifty-five women (29 BRCA1 and 26 BRCA2) (mean age: 50.4 ± 7.7 years [range 35-79]) were included with a mean follow-up after RRSO of 660.9 days (1.8 years) (range 35-1,688 days) (median: 549 days). No intraepithelial (Serous Tubal Intraepithelial Carcinoma)/invasive cancers were found (0%) at RRSO. No vasomotor symptoms at 1 month after surgery were reported by 11/22 (50%) premenopausal women at RRSO. All women (100%) with new "RRSO-caused" vasomotor symptoms with no previous breast cancer initiated postmenopausal hormone therapy. At the final follow-up the satisfaction rate (0-100 visual analog scale points) of the participants was 96.4 ± 8.6 points (range 62-100). To the question "Would you undergo RRSO again if it was proposed today? (0-100 visual analog scale points)" the answer was 99.4 ± 3.2 points (range 79-100). These scores were in general very high and did not change in the different groups according to pre/postmenopausal status at RRSO, cancer survivors versus healthy women at RRSO, BRCA status, hormone therapy users/nonusers after RRSO, "RRSO-caused" symptoms versus not RRSO-caused (P > 0.05).
Conclusions: Findings from this prospective study suggest that satisfaction with RRSO is very high and little dependent on the participants' characteristics at surgery. Women at high risk for ovarian cancer are very satisfied with their choice of risk-reduction strategy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/GME.0000000000001737 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Uptake of Risk-Reducing Salpingo-Oophorectomy and Gynaecologic Surveillance Among Germline BRCA Pathogenic Variants Carriers.
Cancer Med
December 2024
Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
Article Synopsis
- Risk-reducing salpingo-oophorectomy (RRSO) is recommended for women with BRCA1/2 pathogenic variants to prevent ovarian cancer, but many still refuse the surgery despite its benefits.
- A study at a referral center in Italy analyzed 287 women, finding a high uptake rate of 96.1% for RRSO after counseling, although some women were hesitant due to fears about menopause and childbearing.
- The study suggests that a specialized clinic with a supportive team and options for surveillance plays a crucial role in encouraging women to consider risk-reducing surgery.
High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers.
J Natl Cancer Inst
November 2024
Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Article Synopsis
- Risk-reducing salpingo-oophorectomy (RRSO) significantly lowers the risk of high-grade serous carcinoma (HGSC) in women carrying BRCA1/2 genetic variants, but some still develop HGSC after the procedure.
- A study involving 2,519 women found that the 20-year cumulative incidence of HGSC was low (1.5% for BRCA1 and 0.2% for BRCA2 carriers), with particular risk factors identified, such as older age at RRSO and incomplete embedding of RRSO specimens.
- Implementing strict guidelines for timely RRSO and ensuring complete specimen embedding could further minimize the risk of developing HGSC in these patients
Sexual function following risk-reducing salpingo-oophorectomy: a prospective cohort study.
Sex Med
October 2024
Department of Women's and Children's Health, Karolinska Institutet, 117 77 Stockholm, Sweden.
Background: Increased access to and indications for genetic testing will lead to more women undergoing risk-reducing salpingo-oophorectomy (RRSO), with a potential impact on sexual function.
Aim: Our objective was to prospectively investigate (1) sexual function in women with pathogenic variant (PV) in genes, before and 1 year after RRSO, and to compare with a healthy age-matched control group and (2) to study if testosterone levels correlate with sexual functioning after RRSO.
Methods: A prospective observational follow-up study of 43 -PV carriers planned for RRSO and 73 healthy-age matched controls.
Prevalence of cardiometabolic outcomes in women who underwent salpingo-oophorectomy to prevent hereditary breast and ovarian cancer: a meta-analysis.
Fam Cancer
November 2024
Ophir Loyola Hospital, Belém, Pará, 66063-240, Brazil.
Article Synopsis
- Risk reduction salpingo-oophorectomy (RRSO) is a surgery often performed on women with hereditary breast and ovarian cancer (HBOC) syndrome caused by BRCA1 and BRCA2 mutations, which leads to surgical menopause and potential health risks.
- A meta-analysis of six studies involving 1,320 patients examined the rates of cardiovascular and metabolic conditions post-surgery, including myocardial infarction, hypertension, hypercholesterolemia, and type 2 diabetes.
- The results showed that while there were increased prevalence rates for conditions like hypertension (28%) and hypercholesterolemia (27.2%), the overall cardiovascular risk did not significantly increase for women undergoing RRSO.
What happens after menopause? (WHAM): Impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months.
Gynecol Oncol
November 2024
Connors Center for Women's Health and Gender Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Article Synopsis
- Women with BRCA1 and BRCA2 pathogenic variants may experience surgical menopause after RRSO, with previous studies showing increased depressive and anxiety symptoms at 6 and 12 months post-surgery.
- A controlled study tracking 59 women undergoing RRSO and 91 comparison women found that, at 24 months, depressive and anxiety symptoms were not significantly elevated and did not differ between the two groups. However, symptoms at 12 months strongly predicted outcomes at 24 months.
- The study concluded that while symptoms don't seem to escalate after 24 months, persistent symptoms observed at 12 months can indicate ongoing issues, with no significant impact from Menopausal Hormone Therapy on mental health.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!